1. |
Locatelli MA, Curigliano G, Eniu A. Extended adjuvant chemotherapy in triple-negative breast cancer. Breast Care (Basel), 2017, 12(3): 152-158.
|
2. |
Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature, 2000, 406(6797): 747-752.
|
3. |
Vona-Davis L, Rose DP, Hazard H, et al. Triple-negative breast cancer and obesity in a rural Appalachian population. Cancer Epidemiol Biomarkers Prev, 2008, 17(12): 3319-3324.
|
4. |
Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA, 2006, 295(21): 2492-2502.
|
5. |
Rakha EA, El-Rehim DA, Paish C, et al. Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer, 2006, 42(18): 3149-3156.
|
6. |
Kim JY, Jung HH, Ahn S, et al. The relationship between nuclear factor (NF)-κB family gene expression and prognosis in triple-negative breast cancer (TNBC) patients receiving adjuvant doxorubicin treatment. Sci Rep, 2016, 6: 31804.
|
7. |
Kumar P, Aggarwal R. An overview of triple-negative breast cancer. Arch Gynecol Obstet, 2016, 293(2): 247-269.
|
8. |
Lin HY, Sun M, Lin C, et al. Androgen-induced human breast cancer cell proliferation is mediated by discrete mechanisms in estrogen receptor-alpha-positive and-negative breast cancer cells. J Steroid Biochem Mol Biol, 2009, 113(3-5): 182-188.
|
9. |
Wang C, Pan B, Zhu H, et al. Prognostic value of androgen receptor in triple negative breast cancer: A meta-analysis. Oncotarget, 2016, 7(29): 46482-46491.
|
10. |
郑乔丹, 吴文苑. 雄激素受体对人乳腺癌细胞侵袭和迁移影响的研究. 实用医学杂志, 2014, 30(8): 1189-1193.
|
11. |
李铁灵, 郭海峰, 孙治国. 三阴性年轻乳腺癌患者雄激素受体表达与瘤体大小、淋巴转移的相关性研究. 现代肿瘤医学, 2015, 23(10): 1361-1363.
|
12. |
Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst, 2003, 95(19): 1482-1485.
|
13. |
Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer. Cancer, 2007, 109(1): 25-32.
|
14. |
Higgins MJ, Wolff AC. The androgen receptor in breast cancer: learning from the past. Breast Cancer Res Treat, 2010, 124(3): 619-621.
|
15. |
Gasparini P, Fassan M, Cascione L, et al. Androgen receptor status is a prognostic marker in non-basal triple negative breast cancers and determines novel therapeutic options. PLoS One, 2014, 9(2): e88525.
|
16. |
Mohammadizadeh F, Sajadieh S, Sajjadieh H, et al. Androgen receptor expression and its relationship with clinicopathological parameters in an Iranian population with invasive breast carcinoma. Adv Biomed Res, 2014, 3: 132.
|
17. |
杨君, 马学真. AR 和 Ki-67 在三阴性乳腺癌中的表达及临床意义. 青岛大学, 2014: 1-41.
|
18. |
李中琦, 郑怡, 滕晓东, 等. CK5/6 和 AR 在三阴性乳腺癌中的表达及其与临床病理特征的联系. 浙江医学, 2009, 31(1): 49-51.
|
19. |
Asano Y, Kashiwagi S, Goto W, et al. Expression and clinical significance of androgen receptor in triple-negative breast cancer. Cancers (Basel), 2017, 9(1). pii: E4.
|
20. |
McNamara KM, Yoda T, Miki Y, et al. Androgenic pathway in triple negative invasive ductal tumors: its correlation with tumor cell proliferation. Cancer Sci, 2013, 104(5): 639-646.
|
21. |
Ricciardi GR, Adamo B, Ieni A, et al. Androgen receptor (AR), E-cadherin, and Ki-67 as emerging targets and novel prognostic markers in triple-negative breast cancer (TNBC) patients. PLoS One, 2015, 10(6): e0128368.
|
22. |
Kim Y, Jae E, Yoon M. Influence of androgen receptor expression on the survival outcomes in breast cancer: a meta-analysis. J Breast Cancer, 2015, 18(2): 134-142.
|
23. |
Collina F, Cerrone M, Peluso V, et al. Downregulation of androgen receptor is strongly associated with diabetes in triple negative breast cancer patients. Am J Transl Res, 2016, 8(8): 3530-3539.
|
24. |
Barnard ME, Boeke CE, Tamimi RM. Established breast cancer risk factors and risk of intrinsic tumor subtypes. Biochim Biophys Acta, 2015, 1856(1): 73-85.
|
25. |
张继运, 李飞, 沙新海, 等. 新疆汉族与维吾尔族三阴性乳腺癌临床病理特征对比分析. 山东医药, 2012, 52(40): 85-86.
|